HMOX1 and Parkinson disease: Downregulation of HMOX1 by 2 months (–2.5‐fold, p = 3.47 × 10−8) and 6 months (–3.1‐fold, p = 9.58 × 10−12) of treatment supports an antioxidant effect of sargramostim on therapeutic outcomes for PD.